

PRZYPISY

- ¹ Mitchell D. Creinin, MD, Medical abortion regimens: Historical context and overview, *American Journal of Obstetrics and Gynecology*, Vol. 183, No. 2, August 2000, part 2.
- ² Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ³ Mitchell D. Creinin, MD, Medical abortion regimens: Historical context and overview, *American Journal of Obstetrics and Gynecology*, Vol. 183, No. 2, August 2000, part 2.
- ⁴ Mifepristone został zarejestrowany jako środek do wczesnej aborcji przeprowadzanej do 63 dnia ciąży w Wielkiej Brytanii i Szwecji. Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ⁵ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ⁶ NARAL Foundation, The Difference Between Emergency Contraception (ECPs) and Early Abortion Options (RU 486), *available at* <<http://www.naral.org/mediareources/fact/pdfs/ru486.pdf>> (ostatnio odwiedzona 29 stycznia 2003).
- ⁷ Center for Reproductive Rights, Emergency Contraception: Contraception, Not Abortion: An Analysis of Laws and Policy Around the World, April 2002.
- ⁸ Center for Reproductive Law and Policy, *Reproductive Rights 2000: Moving Forward* 37 (2000).
- ⁹ Międzynarodowy Pakt Praw Gospodarczych, Społecznych i Kulturalnych, artykuł 15; *Patrz również* Konwencja praw człowieka i biomedycyny, preambuła.
- ¹⁰ W USA badania przeprowadzone po zarejestrowaniu Mifepistonu przez Urząd Kontroli Żywności i Leków (FDA), ale przed wprowadzeniem tego leku na rynek wykazały, że dostępność Mifepistonu jako środka przeznaczonego do aborcji zwiększy dostępność usług aborcyjnych w USA, przede wszystkim poprzez zwiększenie liczby lekarzy i placówek zdrowotnych świadczących usługi przerwania ciąży. Bonnie Scott Jones, JD and Simon Heller, JD, *Providing Medical Abortion: Legal Issues of Relevance to Providers*, note 2, *American Medical Women's Association, Inc.*, June 2000.
- ¹¹ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ¹² Population Council, Fact Sheet, Mifepristone-Misoprostol Medical Abortion.
- ¹³ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ¹⁴ Mifepriston został zarejestrowany jako środek do przerwania ciąży w 1988 roku we Francji, w 1991 roku w Wielkiej Brytanii i w Szwecji w 1992 roku. Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ¹⁵ Elizabeth Pirruccello Newhall, MD and Beverly Winikoff, MD, MPH, Abortion with mifepristone and misoprostol: Regimens, efficacy, acceptability and future directions, *American Journal of Obstetrics and Gynecology* 2000, Vol. 183, No. 2, S44-S53.
- ¹⁶ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 16, Vol. 34. No. 3, May/June 2002.
- ¹⁷ Royal College of Obstetricians and Gynecologists, *The Care of Women Requesting Induced Abortion*, March 2000.
- ¹⁸ K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 23, Vol. 34. No. 3, May/June 2002.
- ¹⁹ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 24, Vol. 34. No. 3, May/June 2002.
- ²⁰ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 25, Vol. 34. No. 3, May/June 2002.
- ²¹ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ²² Wskaźnik aborcji we Francji wśród kobiet w wieku 15-44 lat wynosił w 1987 i 1997 roku 13 aborcji na 1000 kobiet, a w Anglii i Walii 16 na 1000 w 1990 i 2000 roku. Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 27, Vol. 34. No. 3, May/June 2002.
- ²³ Wskaźnik aborcji zmniejszył się z 21 na 1000 kobiet w 1990 roku do 18 na 1000 w 1999 roku. Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 28, Vol. 34. No. 3, May/June 2002.
- ²⁴ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 57, Vol. 34. No. 3, May/June 2002.
- ²⁵ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, note 58, Vol. 34. No. 3, May/June 2002.
- ²⁶ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ²⁷ Państwa europejskie obejmujące Albanię, Austrię, Francję, Danię, Wielką Brytanię, Łotwę, Holandię, Słowację i Szwecję.
- ²⁸ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ²⁹ Ipas, *Deciding Women's Lives are Worth Saving: Expanding the Role of Midlevel Providers in Safe Abortion Care*, *Issues in Abortion Care* 7, December 2001
- ³⁰ Rachel K. Jones and Stanley K. Henshaw, Mifepristone for Early Medical Abortion: Experiences in France, Great Britain and Sweden, *Perspectives on Sexual and Reproductive Health*, Vol. 34. No. 3, May/June 2002.
- ³¹ Center for Reproductive Rights, *Medical Abortion in Europe*, presentation at Population Council meeting, Paris, Sept. 30-Oct.1, 2002 (on file with Center for Reproductive Rights).
- ³² *Id*
- ³³ Law No. 2001-588 of July 4, 2001, concerning the voluntary interruption of pregnancy and contraception, J.O., July 7, 2001, p. 10823. (Ustawa Nr 2001-588 z 4 lipca 2001 roku dotycząca dobrowolnego przerwania ciąży i antykoncepcji)
- ³⁴ Elizabeth Pirruccello Newhall, MD and Beverly Winikoff, MD, MPH, Abortion with mifepristone and misoprostol: Regimens, efficacy, acceptability and future directions, *American Journal of Obstetrics and Gynecology* 2000, Vol. 183, No. 2, S44-S53.
- ³⁵ Medical abortion to be more widely available in the UK, *Reproductive Health Matters*, Vol. 10, No. 19, May 2002.

Federacja na rzecz Kobiet i Planowania Rodziny

Nowolipie 13/15,
00-150 Warszawa
tel/fax (0 prefiks 22) 635 93 95, 887 81 40
e-mail: federkob@waw.pdi.net
<http://www.federa.org.pl>

The Center for Reproductive Rights

120 Wall St.
New York, NY 10005
(917) 637-3600, (917) 637-3666 (fax)
e-mail: info@reprorights.org
<http://www.reproductiverights.org>